Boston Scientific (BSX) Q4 FY25 earnings call

Boston Scientific delivered a strong Q4 FY25, surpassing financial goals with robust organic sales growth and significant adjusted EPS expansion, driven by innovation across key business units like EP and WATCHMAN. The company provided optimistic 2026 guidance, anticipating continued differentiated performance and margin expansion, despite some near-term product-specific headwinds. Strategic M&A and pipeline advancements are expected to sustain long-term growth.